1. Background {#s1}
=============

The word "cancer" is so fearsome and attention seeking for victims, practitioners and guardians regardless the type of species afflicted. Mammary adenocarcinoma is the third most common cancer in the cats ([@R1]). Eighty percent of the total cases are malignant while 10-20% appeared as benign, sooner or later turn into malignant ([@R2]). Malignant tumors are equally lethal in animals as they are in humans and several animal cancers e.g. mammary adenocarcinoma in the cat are the best model for studying human cancer due to the resemblance in the cell morphology, histopathology, risk factors and prognosis ([@R3],[@R4]). Mammary tumor is a significant health concern in humans and small animals, so especial emphasis was given to ascertain cancer associated sequence number variant (SNVs) and gene expression profiling of *Hspb1* and *Tp53* genes in this neoplasm ([@R5],[@R6]).

Molecular diagnostic biomarkers are getting much attention now in the field of oncology, but still there are few studies regarding the authentication and usage of these markers as screening tools ([@R7]). Disease associated mutations may serve as tumor markers for a particular type of neoplasm. It is one of the major research emphases to diagnose cancer earlier through molecular diagnostics methodologies using single novel signature mutation responsible for the disease outbreak or combination of SNPs or specific haplotype might be helpful for its diagnosis.

*Hspb1*gene was characterized in this study which is located on chromosome E3 at 973, 860-975, 895 position, encodes only one transcript of 1411 bp with 3 exons and ciphers 205 amino acids, having 88% and 86% sequence identity with the dog and human counterpart, respectively ([@R8]). This protein plays its significant role in many processes of tumor development, especially in the cell cycle regulation, immunosurveillance, cell differentiation, and in the apoptotic pathways. High level of this protein was reported in regression stage of cancer and linked with anti-apoptotic activities ([@R9]).

*Tp53* was selected due to being the most variant gene in any type of cancer ([@R10]). It is mutated in more than 50% of all malignancies ([@R11]). In cats, it is located on E1 chromosome, has only one transcript of 1161 bp with 10 exons, and encrypted with 386 amino acids ([@R12]). Tp53 protein behaves as a transcription factor, maintains cell growth and genomic integrity ([@R13],[@R14]).

2. Objectives {#s2}
=============

The objectives of the current study are to ascertain cancer associated DNA mutations and expression profiles in *Hspb1*and *Tp53* genes in cancer and disease free controls. A sensitive and robust, endpoint conventional long-range PCR technique was used to characterize these genes using "Sequencher" software and gene expression profiling through RT-qPCR by TaqMan assay chemistry, which will give us better insight to understand genetic variations and gene expression data simultaneously in cat mammary cancer to improve its clinical diagnosis.

3. Materials and Methods {#s3}
========================

3.1. Sample Collection {#s3-0-1}
----------------------

Six mammary tumor tissues and peripheral blood of affected Siamese cat including one normal domestic random bred cat were collected through standard protocol ([Table 1](#T1){ref-type="table"}). All neoplastic tissues were excisional biopsies. All tissue masses were storedin -86ºC for DNA/RNA extraction and downstream processes ([@R15]).

3.2. DNA and Total RNA Extraction {#s3-0-2}
---------------------------------

TaiGen genomic DNA tissue kit (TaiGen Biotechnology Co., Ltd, Neihu Dist., Taipei, Taiwan) was used to extract DNA from the tumorous tissues ([@R16]). While genomic DNA from blood was extracted using GF-1 tissue blood combi DNA extraction kit (Vivatis Technologies SDN. BHD. Selangor Darul Ehsan, Malaysia). DNA quantification was done using NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 50 ng.μL^-1^ concentration of DNA was used for downstream PCR amplifications.

Similarly, total RNA was extracted from cancerous and normal tissues using Thermo Scientific GeneJet RNA purification kit ([@R17]) following to the pulverization of the tissues in the liquid nitrogen. TriZol reagent method was also used to extract total RNA from minute tissues ([@R18]). RNA integrity was confirmed by agarose gel electrophoresis and concentration was measured by NanoDrop spectrophotometer.

3.3. Primer and Probes {#s3-0-3}
----------------------

Long-range primers were designed from DNA sequence ID ENSFCAT00000026034 and ENSFCAT00000009625 for *Hspb1* and *Tp53* through the application of Primer3 and NetPrimer software (PREMIER Biosoft International, Palo Alto, CA) ([@R19],[@R20]). Primer express software (Applied Biosystem, USA) was used to design the primer-probe sequences of the *GAPDH* gene as an endogenous control for normalization ([@R21]). *Hspb1*and *Tp53* primer-probes expression assays were purchased with FAM flourophore while *GAPDH* probe was labeled with VIC reporter dye on 5´ end and TAMRA as a quencher on the 3´ ([Table 2](#T2){ref-type="table"}).

3.4. PCR Amplification {#s3-0-4}
----------------------

Long-range PCR was performed using Applied Biosystem thermocycler at 94ºC temperature for 2 min as initial denaturation, then 10 cycles at 94ºC as cyclic denaturation for 10 sec, annealing at 61v for 30 sec and extension temperatures at 68ºC was adopted for 3 and 5 min because the product size were 2303 and 3610 bp in *Hspb1* and *Tp53* genes respectively. Later on, 30 cycles were run with annealing at 59ºC an extension was done with an increment of 20 sec per cycle. The final extension was done with at 72ºC for 5 min. Long-range PCR kit was used, which has high-fidelity polymerase with final concentration of 1.8 U, PCR 10X enhancer-A with final concentration of 1X, PCR additive 5% dimethyl sulfoxide (DMSO) for GC-rich region amplification and 10X reaction buffer with final concentration of 1X ([@R22],[@R23]).

3.5. Gel Electrophoresis and Data Analysis {#s3-0-5}
------------------------------------------

Electrophoresis with 1.5% agarose gel was conducted for 50 min ([Figure 1](#F1){ref-type="fig"}). Post PCR specific products were purified by treating with ExoSAP ([@R24]) (ExoSAP-IT PCR Product Clean up, Santa Clara, CA, USA). Sequencing was done with ABI BigDye termi-nator sequencing Kit (Applied Biosystems, Foster City, CA, USA). "Sequencher" 5.1 software (Gene Codes Corporation, Ann Arbor, MI, USA) was used for sequence analysis ([@R25]) (Sequencher® version 5.2 sequence analysis software, Gene Codes Corporation, Ann Arbor, MI USA).
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###### The signature of the exonic/intronic mutations of the *Hspb1* gene in the mammary tumors of the Siamese cat

  ------------------------------- ----------- ------------------------- ------------ -------------- -------------- ------------ ------------ ------------------ ------------ ----------- ----------- ----- ----- -----
  **Animal ID**                   **Age**\    **Animal /Tissue Type**   **Exon 1**   **Intron 1**   **Intron 2**   **Exon 3**   **3\'UTR**   **3\' Flanking**                                                    
                                  **(Yr)**                                                                                                                                                                       

  **-338**\                       **-305**\   **-288**\                 **-286**\    **-166**\      **c.34**\      \            **1490**\    **1514-1517**\     **c.773**\   **1868**\   **2193**\               
  **C\>T**                        **T\>C**    **G\>A**                  **A\>G**     **T\>A**       **C\>A**       **1326**\    **C\>G**     **Del**\           **A\>T**     **A\>T**    **C\>T**                
                                                                                                                   **T\>C**                  **GTCT**                                                            

  Reference                       \-          Normal                    C            T              G              A            T            C                  T            C           TTCT        A     A     C

  Normal (Domestic random bred)   Un-known    Control/Blood             C            C              A              G            T            C                  T/C          C/G         GTCT        A     A     C

  CP7                             7           Case/Tumor                T            C              G              G            A            C/A                T            G           Del         A     A     C/T

  CP13                            \           Case/Tumor                C/T          T/C            G              A/G          T/A          C                  T/C          C           GTCT        A/T   A/T   C
                                  6                                                                                                                                                                              

                                              Case/Blood                C/T          T/C            G              A/G          A            C                  T/C          C           GTCT        A     A     C

  CP13A                           8           Case/Tumor                C/T          T/C            G              A/G          T/A          C                  T/C          C           GTCT        A/T   A/T   C

  CP16                            7           Case/Tumor                C/T          T/C            G              A/G          T/A          C/A                T            C/G         +/-         A     A     C

                                              Case/Blood                C/T          T/C            G              A/G          A            C/A                T            C/G         +/-         A     A     C

  CP28                            2           Case/Tumor                T            C              G              G            A            C                  T            G           Del         A     T     C/T

  Amino acid change                           \-                                                                                             (Cys)\                                                              
                                                                                                                                             Synonymous                                                          
  ------------------------------- ----------- ------------------------- ------------ -------------- -------------- ------------ ------------ ------------------ ------------ ----------- ----------- ----- ----- -----

###### The signature of the exonic/intronic mutations of the *Tp53* gene in mammary tumor of the Siamese cat

  -------------------------------- ---------- ----------------- -------------- ------------- ------------- -------------- ------------ -------------- -------------- ------------ -------------- -------------- ------------ ---------------- ----------------- ----------- ----------- ----------- ----------- ------------- ----------- ----------- ------------- ----------- ----------- ----------- ----------- ----------- ----- --- -----
  **Animal ID**                    **Age**\   **Animal/**\      **Intron 1**   **Intron2**   **Exon 3**    **Intron 3**   **Exon 4**   **Intron 5**   **Intron 6**   **Exon 7**   **Intron 7**   **Intron 8**   **Exon 9**   **Intron 9**     **3\'Flanking**                                                                                                                                                                             
                                   **(Yr)**   **Tissue Type**                                                                                                                                                                                                                                                                                                                                                                             

  **202**\                         **278**\   **c.105**\        **769**\       **776**\      \             **c.465**\     **1474**\    **1514**\      **1515**\      **1555**\    **1756**\      **Ins**\       **2002**\    **c.859 G\>T**   **2167**\         **2217**\   \           **2340**\   **2415**\   **c.1050**\   **2476**\   **2521**\   **2737**\     **2854**\   **2941**\   **2943**\   **3051**\   **3320**\             
  **C\>G**                         **G\>C**   **A\>G**          **C\>T**       **C\>T**      **958**\      **T\>C**       **T\>C**     **C\>T**       **A\>G**       **G\>C**     **C\>T**       **1990**       **C\>T**                      **A\>G**          **T\>C**    **2334**\   **G\>A**    **T\>C**    **G\>A**      **C\>T**    **G\>A**    **G\>A**      **G\>A**    **G\>A**    **A\>G**    **G\>A**    **T\>C**              
                                                                                             **Ins (A)**                                                                                                                                                                    **C\>T**                                                                                                                                                      

  Reference (Abyssinian)           \-         Normal            C              G             C             C              C            \-             T              T            C              A              G            C                \-                C           G           A           T           C             G           T           G             C           G           G           A           G           A     G   C

  Control (Domestic random bred)   Un-known   Normal/ Blood     G              C             G             C              C            A              T              T            T              G              C            T                \-                C           G           G           C           C             G           T           A             C           A           A           G           G           G     G   T

  CP7                              7          Tumor             C/G            G             A/G           C              C            A              T/C            T/C          C              A              C            C                \-                C           G           A           T           C             G           T           G/A           C           G           G/A         G           G/A         G     G   C

  CP13                             \          Tumor             C              G             A             C              C            A              T              T            C              A              G            C/T              \-                C           G           A/G         T           C             G           T           G/A           C           G/A         G           G/A         G           A/G   G   T/C
                                   6                                                                                                                                                                                                                                                                                                                                                                                                      

                                              Blood             C              G             A             C              C            A              T              T            C              A              G/C          C/T              \-                C           G           A           T/C         C             G           T           G/A           C           G           G           A           G           A/G   G   T/C

  CP13A                            8          Tumor             C              G             G             C              C            A              T              T            C              A              G            C/T              \-                C           G           A/G         T/C         C             G           T           G/A           C           G/A         G           A           G           A/G   G   T/C

  CP16                             \          Tumor             C              G             A             C              C            A              T              T            C              A              G            C                \-                C           G           A           T           C             G           T           G             C/T         G           G           A           G           A     G   C
                                   7                                                                                                                                                                                                                                                                                                                                                                                                      

                                              Blood             C              G             A             C/T            C            A              T              T            C              A              G            C                \-                C           G           A           T           C             G           T           G             C/T         G           G           A           G           A     G   C

  CP28                             2          Tumor             G              C             G             C              T            A              C              C            C              A              G            C                T                 T           T           G           T           T             A           C           G             C           A           G           G           A           G     A   C

  Amino acid change                                                                                                                                   (Tyr)\                                                                                                                Non-sense                                                                 (Arginine)\                                                                         
                                                                                                                                                      Synonymous                                                                                                                                                                                      Synonymous                                                                          
  -------------------------------- ---------- ----------------- -------------- ------------- ------------- -------------- ------------ -------------- -------------- ------------ -------------- -------------- ------------ ---------------- ----------------- ----------- ----------- ----------- ----------- ------------- ----------- ----------- ------------- ----------- ----------- ----------- ----------- ----------- ----- --- -----

###### Tabulated representation and calculation of *Tp53* gene expression in *Felis catus*

  ---------------- ---------- ------------- --------- --------- ----------- ------------ ---------- ---------- -------------- --------- --------- ----------- ----------- ---------- ---------- ---------- -----------------
  **Sample ID**    **Well**   **Ct-TP53**   **Min**   **Max**   **Range**   **Stan.**\   **Mean**   **Well**   **Ct-GAPDH**   **Min**   **Max**   **Range**   **Stan**\   **Mean**   **ΔCt.**   **ΔΔCt**   **Fold-change**
                                                                            **Dev.**                                                                          **Dev.**                                     

  CP7              A1         34.65                                                                 A4         30.349                                                                                      

                   A2         34.89         34.65     35.27     0.62        0.26         34.94      A5         33.336         30.35     36.38     6.03        2.46        33.35      1.58       0.97       0.51

                   A3         35.271                                                                A6         36.377                                                                                      

  CP13             A7         35.937                                                                B2         37.264                                                                                      

                   A8         36.35         35.94     36.74     0.80        0.33         36.34      B3         37.123         36.97     37.26     0.29        0.12        37.12      -0.78      -1.39      2.62

                   B1         36.736                                                                B4         36.97                                                                                       

  CP13A            B5         23.877                                                                B8         31.938                                                                                      

                   B6         24.103        23.88     24.29     0.41        0.17         24.09      C1         31.92          31.87     31.94     0.07        0.03        31.91      -7.82      -8.43      344.57

                   B7         24.291                                                                C2         31.869                                                                                      

  CP16             C3         27.429                                                                C6         32.647                                                                                      

                   C4         27.355        27.28     27.43     0.15        0.06         27.36      C7         32.51          32.36     32.65     0.29        0.12        32.51      -5.15      -5.76      54.19

                   C5         27.281                                                                C8         32.358                                                                                      

  CP28             D1         25.722                                                                D4         33.453                                                                                      

                   D2         25.391        25.32     25.72     0.40        0.17         25.48      D5         33.21          33.21     33.45     0.24        0.11        33.30      -7.82      -8.43      344.65

                   D3         25.324                                                                D6         33.231                                                                                      

  Normal control   D7         24.991                                                                E2         25.034                                                                                      

                   D8         24.893        24.89     25.16     0.27        0.11         25.01      E3         23.879         23.88     25.03     1.16        0.48        24.40      0.61       \-         \-

                   E1         25.16                                                                 E4         24.298                                                                                      
  ---------------- ---------- ------------- --------- --------- ----------- ------------ ---------- ---------- -------------- --------- --------- ----------- ----------- ---------- ---------- ---------- -----------------

###### Tabulated representation and calculation of the Hspb1 gene expression levels in Felis catus

  ---------------- ------ ---------- ------- ------- ------- ------- ------- ------ ---------- ------- ------- ------- ------- ------- ------- ------- -------------
  Sample \#        Well   Ct-HSPB1   Min     Max     Range   Stan\   Mean    Well   Ct-GAPDH   Min     Max     Range   Stan\   Mean    ΔCt.    ΔΔCt    Fold-change
                                                             Dev.                                                      Dev.                            

  CP7              A1     35.532                                             A4     30.249                                                             

                   A2     34.897     34.40   35.53   1.13    0.46    34.94   A5     33.209     30.25   36.00   5.75    2.35    33.15   1.79    1.25    0.42

                   A3     34.404                                             A6     36                                                                 

  CP13             A7     27.846                                             B2     37.264                                                             

                   A8     28.567     27.85   28.57   0.72    0.30    28.18   B3     37.69      36.97   37.69   0.72    0.30    37.31   -9.12   -9.66   811.62

                   B1     28.137                                             B4     36.97                                                              

  CP13A            B5     23.877                                             B8     31.938                                                             

                   B6     24.1       23.88   24.29   0.41    0.17    24.09   C1     31.909     31.87   31.94   0.07    0.03    31.91   -7.82   -8.36   327.65

                   B7     24.291                                             C2     31.869                                                             

  CP16             C3                                                        C6     32.647                                                             

                   C4     25.55      25.23   26.08   0.85    0.35    25.62   C7     32.39      32.36   32.65   0.29    0.13    32.47   -6.84   -7.38   167.00

                   C5     26.081                                             C8     32.358                                                             

  CP28             D1     25.345                                             D4     31.564                                                             

                   D2     25.591     25.35   25.88   0.53    0.22    25.60   D5     31.701     31.56   31.87   0.30    0.12    31.71   -6.11   -6.65   100.22

                   D3     25.875                                             D6     31.867                                                             

  Normal Control   D7     24.987                                             E2     24.886                                                             

                   D8     25.178     24.77   25.18   0.41    0.17    24.98   E3     23.55      23.55   24.89   1.34    0.63    24.44   0.54    \-      \-

                   E1     24.765                                             E4     24.878                                                             
  ---------------- ------ ---------- ------- ------- ------- ------- ------- ------ ---------- ------- ------- ------- ------- ------- ------- ------- -------------

3.6. Reverse Transcription {#s3-0-6}
--------------------------

Target RNA was reverse transcribed using RevertAid first strand cDNA Synthesis Kit (Thermo Fisher Scientific, Pittsburg, PA, USA) ([@R26]). Synthesis of first strand cDNA was performed with oligo (dT) 18 primer and random hexamer primers.

3.7. RT-qPCR Detection Chemistry and Experimental Design {#s3-0-7}
--------------------------------------------------------

TaqMan primer-probe hydrolysis chemistry was adopted by using Applied Biosystem 7500 Real-Time System. Twenty μL reaction volume was used, which contains 1 μL 20X TaqMan assay, 10 μL of 2x TaqMan master mix, 4 μL of cDNA with 5 ng.μL^-1^ concentration, plus 5 μL of RNase-free water. Then 40 cycles of reaction were run for amplification (Applied Biosystem, USA). All reactions were designed using singleplex two-step qPCR. Both targets (Hspb1 and Tp53) and GAPDH genes were amplified in triplicate in cases and controls and folds change were obtained from Ct values.

3.8. RT-qPCR Data Analysis {#s3-0-8}
--------------------------

Livak method/ΔΔCt method was used in which fold change expression in cancer (Target) vs. normal samples (Calibrator) and constitutively expressed *GAPDH* (Reference) genes were calculated by the following formula ([@R27]).

ΔCt (Test) = Ct (Target)-Ct (Reference)

ΔCt (Calibrator) = Ct (Target)-Ct (Reference)

ΔΔCt = ΔCt (Test)-ΔCt (Calibrator)

Fold Change = 2^-ΔΔCt^

4. Results {#s4}
==========

4.1. Hspb1 Mutational Spectrum {#s4-0-1}
------------------------------

The reference control sequence of random bred cat was used to align the sequences of our tumour samples ([@R9]). *Hspb1* gene of the *Felis catus* has 86% nucleotide identity and 88% protein homology with the human counterpart. No non-synonymous nucleotide alterations were identified in the DNA from five tumorous tissues or in the DNA isolated from blood. Twelve variants were identified in the UTRs, intronic and 5´ flanking regions, but none of them were noticed in cancer cases or in the control. A 4 bp intronic deletion (GTCT) was identified in three cancer samples (CP7, CP16, Cp28), the normal cat has the same sequence of GTCT, but it is absent in the reference sample. Sample (CP16) showed heterozygosity at this position both in somatic tissues and in the blood DNA, which has 4 bp deletions in one allele, while the other allele is same as the wild type. Two 5´ UTR and one 3´ UTR mutation showed a gain of heterozygosity in the tumor as compared to the DNA extracted from blood sample within the same individual.

Out of the total ten altered positions excluding UTR and 5´ flanking region, half of the mutation were observed as transversion, while the remaining half appeared as transition mutations ([Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}).
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4.2. Tp53 Mutational Landscape {#s4-0-2}
------------------------------

The overall gain of heterozygosity was observed in the exon 3, 4, and 9 ([Table 4](#T4){ref-type="table"}). c.105 locus in exon 3 is homozygous (A) in two samples (CP13, CP16) and heterozygous (A/G) in (CP7), but doesn't change the amino acid. The exon 4 c.465 locus is heterozygous (C/T) in (CP7) while homozygous (C) in another (CP28) sample. Also, it appears to be synonymous. Locus c.859 in exon 7 is homozygous (T) in one sample (CP28) and appeared asa non-sense mutation. Similarly, exon 9 is heterozygous (G/A) at position c.1050 in three cases (CP7, Cp13, CP13A) and proved to be synonymous as well.

Different polymorphic sites were observed in each of the introns 1, 2, and the 3´flanking region at 202, 278 and 3320 loci, respectively. Intron 7 has two hotspots at 2167A\>A/G and 2217T\>T/C. Introns 3, 6, and 8 have three variant positions in each at positions (769,776,958), (1756,1900,2002), and (2334,2340,2415) respectively. Similarly, introns 5 and 9 have different 4 and 7 point mutation correspondingly. Intronic mutations give us clues regarding how somatic mutations accumulate in a micro-evolutionary process of cancer development. Out of the total 28 polymorphic positions in this gene, 4 positions are transversion, while 24 are transitional changes ([Table 4](#T4){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}).

4.3. Differential Expression of Tp53 {#s4-0-3}
------------------------------------

Two-step singleplex RT-qPCR was conducted on all mammary tumor cancer cases in triplicate and standardized cDNA of 5 ng.μL^-1^ concentration was used as a template, which was prepared from 100 ng.μL^-1^ stock RNA. Fold change difference expression values were obtained by using ΔΔCt/comparative Ct method. Calculations were performed using ΔCt of *Tp53* gene in all mammary tumor samples. Similarly, ΔCt values of *GAPDH* were also calculated in all cancer samples, while ΔCt calibrator was calculated (0.61) from the mean Ct target *Tp53* subtracted from mean Ct reference/ endogenous *GAPDH* of normal diseased free cat tissues.

ΔΔCt values were obtained by subtracting ΔCt target from the ΔCt calibrator, then this value underwent to the negative exponential power of 2, which represents the efficiency of the assay. Finally, differential expression values as fold change were obtained mentioned in the [Table 3](#T3){ref-type="table"}.

Four mammary tumors were revealed up-regulated for *Tp53* gene, with the fold change of maximum 344.65, while one sample (CP7) showed down-regulation of this gene ([Figure 3](#F3){ref-type="fig"}).
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4.4. Hspb1 Differential Expression {#s4-0-4}
----------------------------------

Similarly, ΔCt of normal disease-free samples (Calibrator) was calculated (0.54) in Felis catus, which is meant Ct target Hspb1 gene in normal tissues subtracted from the mean Ct of *GAPDH* from the same normal tissues ([Table 4](#T4){ref-type="table"}).

Alike *Tp53* up-regulation (in CP13, CP13A, CP16, and CP26), Hspb1 gene is subject of up-regulation in the same samples, while CP7 sample was found to become down-regulated same as *Tp53* ([Figure 4](#F4){ref-type="fig"}).

![](ijb-14-202-g004){#F4}

5. Discussion {#s5}
=============

It is undoubtedly established that accumulation of mutations leads to cancer or cell death. *Hspb1* as a diagnostic marker are not so much informative, but they are expedient indicators for carcinogenesis in some tissues and predict the differentiation and aggressiveness of few cancers ([@R28]). This gene has been widely studied in human cancers ([@R29]), it has hotspot motif at functional promoter rs2868371 and G1271C ([@R30]). Similarly in veterinary species, Austrian feline solid carcinoma of mammary glands, where Arg CGG-TGG Tyr variant was found in exon 8 of *Tp53* ([@R31]). The current study did not report this variant probably due to breed or geographical population differences. But it has been found that *Tp53* exon 3, 4, 7 and 9 are more variable as compared to other exons and codon 35, 155, 287 and 350 were found mutant. Codons 35, 155, and 350 are synonymous while the codon 287 terminates the peptide chain and turned into the stop codon.

*Tp53* gene was characterized in FVAS where 8 SNPs along with (T) insertions were found in exon 5, 6, 7 and 8 ([@R32]). Codon 163 and positions 14,246, 247, and 259 of intron 7 were also altered ([@R33]). The change in the c.105 locus of the *Tp53* in samples CP7 (c.105G\>A/G), CP13 (c.105G\>A) and CP16 (c.105G\>A) were observed ([Table 2](#T2){ref-type="table"}). The same locus was reported polymorphic in human pancreatic cancer ([@R34]), hepatocarcinoma ([@R35]), breast and ovarian cancers ([@R36]).

Locus c.465C\>T of the *Tp53* was found altered in‏ CP7 (c.465T\>T/C) and CP28 (c.465T\>C) samples‏ ([Table 2](#T2){ref-type="table"}). Same locus were reported to be altered in‏ eight different studies in human breast cancer ([@R37],[@R38]),‏ ovarian cancer ([@R39]), hepatocarcinoma ([@R40]), colorectal‏ cancer ([@R41]), endometrial tumor ([@R42]), sinonasal cancer‏ ([@R43]), esophageal adenocarcinoma ([@R44]), while one‏ study has shown c.465C\>A change, which was on‏ esophageal SCC in Chinese population ([@R45]). This‏ locus appeared as synonymous in all these studies.‏ Locus c.859 was also found very informative in‏ human studies, as we observed here in cat mammary‏ tumor of CP28 sample, this transversion of‏ (c.859G\>T) turned into stop codon in this sample‏ which is a transitional change of (c.859G\>A) in DNA‏ binding site of coding strand in five human studies of‏ bladder cancer ([@R46]), hepatocellular carcinoma ([@R47]),‏ skin SCC ([@R48]), aerodigestive tract ([@R49]), gastric cancer‏ ([@R50]), and changed glutamic acid to lysine (p.E287K) in‏ the protein. Another transversion change of ‏ c.859G-\>T‏ was also noticed in the five different studies on this‏ locus including Burkitt Lymphoma and chronic lymphocytic‏ leukemia ([@R51]), non-small-cell lung cancer‏ ([@R52]), bladder carcinoma ([@R53]), thyroid carcinoma ([@R54]),‏ esophageal carcinomas ([@R55]) in which glutamic acid‏ was ‏ changed to stop a codon (p.E287X) in the protein‏ as well as in the present study in this cat mammary‏ tumor (CP28) ([Table 2](#T2){ref-type="table"}).

The c.1050 position of the *Tp53* in cats mammary‏ tumor was found altered in three cancer samples (CP7,‏ CP13, CP13A), in which c.1050G\>G/A change was‏ observed ([Table 2](#T2){ref-type="table"}), which appeared as synonymous. In‏ one of the human aristolochic acid-associated urothelial‏ cancer in Taiwan population, this locus was also‏ found to be altered at c.1050C-\>G and synonymous in‏ nature. This point mutation was transversion in the‏ DNA coding strand, which encodes an amino acid in‏ alpha helix structure of this protein ([@R56]). Our studied‏ mammary cases have shown alterations in exon 3, 4, 7,‏ and 9 of Tp53 gene. A 4 bp deletion was found in the‏ intron 2 of the Hspb1 gene in the three cat mammary‏ tumors (CP7, CP16, CP28), which is homozygous in‏ two (CP7, CP28), and heterozygous in one neoplastic‏ tissue, as well as the blood of one animal (CP16,‏ CP16b) samples.

5.1. Comparison of Hspb1 Polymorphism {#s5-0-1}
-------------------------------------

Cross-tissue (germ-line vs somatic) mutational comparison of the cat's Hspb1 gene was re-evaluated and revealed that the mostly altered loci are same in neoplastic tissues and blood of the same animal CP13 and CP16, especially in the exonic regions, but few of the intronic positions show heterozygosity. Similarly, (-)166 locus in 5´UTR of exon 1 in two cases: CP13 and CP16 acquired the same heterozygous (T/A) mutation in tumorous tissues while blood DNA are homozygous (A) at this locus. In sample CP13 at 773 position of 3´UTR of Hspb1 gene found heterozygous (A/T) in cancerous tissues, while homozygous (A) in the blood ([Table 1](#T1){ref-type="table"}). Other polymorphic loci were observed to be the same in both tissues. Similarly, 3´UTR locus 1868 in CP13 tumorous tissue is also different from the blood. It is homozygous (A) in blood, while heterozygous (A/T) in neoplastic tissues ([Table 2](#T2){ref-type="table"}).

5.2. Comparison of Tp53 Polymorphism {#s5-0-2}
------------------------------------

Cross-tissue mutation comparison (germ-line versus‏ somatic) was also conducted for *Tp53*.‏ Comparison of sample ID CP13 and CP16 was conducted‏ which revealed that exonic regions are the same‏ between the two tissue types while five loci in the‏ intronic region in CP13 are different in this crossexamination‏ of polymorphic sites. Few loci in blood‏ are different e.g. gene position 1555 in intron 5 is heterozygous‏ (G/C) in blood instead of homozygous (G)‏ in neoplastic tissue, position 2167 in intron 7 is‏ homozygous (A) in blood instead of heterozygous‏ (A/G) in cancerous tissue. Similarly, two positions‏ 2521 and 2854 in intron 9 are homozygous (G) and (A)‏ instead of heterozygous (G/A) in neoplastic tissues of‏ the sample CP13. CP16 sample was found heterozygous‏ (C/T) instead of homozygous (C) in cancerous‏ tissues in intron 3 at position 769 ([Table 2](#T2){ref-type="table"}).

Regarding the *Hspb1* and *Tp53* expression in relation‏ to different mutations, up-regulation of *Tp53* was‏ observed in 4 mammary tumors (CP13, CP13A, CP16,‏ and CP28). Two tumors samples (CP13, CP16)‏ showed fold change of 2.62 and 54.19 respectively,‏ while two of the tumor samples (CP13A, CP28)‏ showed almost same up-regulation of 344.57 and‏ 344.65, respectively. Significant up-regulation of *Tp53* expression, as compared to the calibrator, is much‏ more informative in differential diagnosis as compared‏ to those markers which have slightly higher overexpression‏ ([Table 3](#T3){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}).

*Tp53* up and down regulated samples are significantly‏ different in their mutational landscape, as upregulated‏ samples (CP13, CP16) have 105G\>A common‏ mutation in exon 3. Likewise, (CP13, CP13A)‏ have common mutation of 1050G\>G/A in exon 9,‏ while up-regulated sample (CP28) was quite different‏ from their counterparts, which has two homozygous‏ variants of 465T\>C in exon 4 and 859G\>T in exon 7.‏ Different mutations in these four samples which are‏ different from the down-regulated sample are 202C in‏ intron 1, 278G in intron 2, 776C in intron 3, 1474T in‏ intron 5 in (CP13, CP13A, and CP16), while 202G,‏ 278C, 776T, 1474C in (CP28).

Down-regulated sample (CP7) of *Tp53* gene were‏ found heterozygous at 105G\>G/A in exon 3,‏ 465T\>T/C in exon 4 and 1050G\>G/A in exon 9 loci,‏ which are homozygous (A), (T) and (G) in up-regulated‏ samples of the mammary tumors respectively.‏ These loci 202C/G, 769C, 278G, 1474T/C, 1555C,‏ 2737G/A, 2941G/A of (CP7) are different from the‏ above mentioned up-regulated samples ([Table 3](#T3){ref-type="table"}). Four‏ samples (CP13, CP13A, CP16, and CP28) showed upregulation‏ of the *Hspb1* out of the total five tumors‏ (Table 4, [Figure 4](#F4){ref-type="fig"}). Minimum up-regulation of 100.22‏ fold change was observed in one sample (CP28). One‏ of the tumor sample CP13A showed almost same‏ expression of *Hspb1* and *Tp53* in the range of 327.65‏ and 344.57 respectively. The up-regulation trend of‏ *Hspb1* gene expression can be correlated with common‏ heterozygous mutations of 166T\>T/A,‏ 286A\>A/G, 305T\>T/C, and 388C\>C/T in three upregulated‏ samples (CP13, CP13A, and CP16) in exon‏ 1, while (CP28) sample has up-regulation of *Hspb1* gene with all homozygous changes on the same loci‏ 166T\>A, 286A\>G, 305T\>C, and 388C\>T.

One of the worth mentioning change was 1514-‏ 1517del4 that has been observed in all four up-regulated‏ samples in intron 2 of *Hspb1*. Similarly,‏ 1326T\>T/C change was observed in intron 1 and‏ 1868A\>A/T in 3´UTR in two up-regulated samples‏ (CP13, CP13A) while the third up-regulated sample‏ (CP16) was found heterozygous on 1514-1517 locus‏ with additional change of 1490C\>C/G in intron 2. The‏ fourth up-regulated sample of (CP28) showed 1514-1517del4 change along with an additional change of‏ 1868A\>A/T in 3´UTR. One mammary tumor sample‏ (CP7) showed down-regulation of *Hspb1* as compared‏ to the calibrator, which showed fold change of 0.42.‏ Down-regulation might be associated with homozygous‏ locus of 286A\>G, 305T\>C and 338C\>T. Downregulated‏ sample has homozygous variant on the same‏ three loci as compared to the heterozygous variants in‏ up-regulated samples. These changes are similar to‏ (CP28) but with the difference in one locus of‏ 166T\>A. Intronic regions are also found altered in this‏ single down-regulated sample (CP7), in which 1514-1517Del4 and 1490C\>G changes were found in the‏ intron 2.

6. Conclusions {#s6}
==============

*Tp53* was found to be more polymorphic than‏ *Hspb1*. Exon 3, 4 and 9 have one synonymous mutant‏ site in each, while one mutant in exon 7 was appeared‏ as non-sense. Introns 1, 2 and 9 were found polymorphic‏ with 1, 1, and 7 variants respectively. Introns 3, 6‏ and 8 have three mutant loci while intron 5 was‏ observed with four mutant loci. Intron 6 has an insertion‏ of 1 bp at the position 1990 in sample CP28.‏ Similarly, exon 1 in *Hspb1* has six polymorphic sites‏ with one synonymous mutation, while remaining five‏ are located in the upstream region. Exon 3 was also‏ observed mutated at a single at genomic position of 1326 in its intronic region. Regarding the gene expression,‏ overall up-regulation of the both genes was‏ observed in this cat neoplasm as compared to normal.
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